N-[3-Fluoro-5-(3-pyrindyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide manufacturers
- SB228357
-
- $41.00
-
2026-07-27
- CAS:181629-93-6
- Purity: 99.82%
- Supply Ability: 10g
|
| | N-[3-Fluoro-5-(3-pyrindyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide Basic information |
| Product Name: | N-[3-Fluoro-5-(3-pyrindyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide | | Synonyms: | SB 228357;N-[3-Fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide;N-[3-fluoro-5-(3-pyridinyl)phenyl]-5-methoxy-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide;1H-Indole-1-carboxamide, N-[3-fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-;SB-228357,SB228357;SB228357, 10 mM in DMSO;N-(3-Fluoro-5-(pyridin-3-yl)phenyl)-5-methoxy-6-(trifluoromethyl)indoline-1-carboxamide;N-[3-Fluoro-5-(3-pyrindyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide | | CAS: | 181629-93-6 | | MF: | C22H17F4N3O2 | | MW: | 431.38 | | EINECS: | | | Product Categories: | | | Mol File: | 181629-93-6.mol | ![N-[3-Fluoro-5-(3-pyrindyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide Structure](CAS/GIF/181629-93-6.gif) |
| | N-[3-Fluoro-5-(3-pyrindyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide Chemical Properties |
| Boiling point | 625.4±55.0 °C(Predicted) | | density | 1.398±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: ~8 mg/mL, soluble | | form | solid | | pka | 9.72±0.70(Predicted) | | color | white |
| | N-[3-Fluoro-5-(3-pyrindyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide Usage And Synthesis |
| Uses | SB 228357 is a SR-2C/SR-2B receptor antagonist. It is used in the treatment of irritable bowel syndrome (IBS). | | Definition | ChEBI: SB 228357 is an indolyl carboxylic acid. | | Biological Activity | 5-HT 2C/2B receptor antagonist (pK i values are 7.0, 8.1 and 9.1 at 5-HT 2A , 2B and 2C receptors respectively). Displays inverse agonism in a 5-HT-stimulated PI hydrolysis model of 5-HT 2C receptor function. Orally active in vivo . | | in vivo | SB228357 (0-10 mg/kg; oral administration; for 90 minutes; male Sprague Dawley rats) treatment significantly reverses Haloperidol-induced catalepsy[2]. | Animal Model: | Male Sprague Dawley rats (200-250g) injected with Haloperidol[2] | | Dosage: | 0 mg/kg, 0.32 mg/kg, 1 mg/kg, 3.2 mg/kg, 10 mg/kg | | Administration: |
Oral administration; for 90 minutes | | Result: | Significantly reversed Haloperidol-induced catalepsy.
|
| | IC 50 | 5-HT2A Receptor: 6.9 (pKi); 5-HT2C Receptor: 9 (pKi); 5-HT2B Receptor: 8 (pKi) | | storage | Store at RT |
| | N-[3-Fluoro-5-(3-pyrindyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide Preparation Products And Raw materials |
|